Enhancement or Suppression of ACE Inhibitory Activity by a Mixture of Tea and Foods for Specified Health Uses (FOSHU) That Are Marketed as “Support for Normal Blood Pressure”
The ACE inhibitory activities of mixtures of FOSHUs (Healthya, Goma-Mugicha, Lapis Support and Ameal) were examined in order to identify any antihypertensive interactions. Among combinations of Healthya with other samples that contain active peptides, only that with Ameal was found to have no inhibitory activity. Enhanced activity was observed in 2 other mixtures. The activity of a mixture of tea polyphenols and the whey component extracted from an Ameal solution was significantly decreased, thus demonstrating that whey protein lowered the ACE inhibitory activity of Healthya. Although oral administration of tea polyphenols alone significantly decreased SBP in SHR at 2 and 4？hr, combined administration with Ameal failed to decrease SBP at the same time points. In conclusion, the simultaneous intake of tea and FOSHUs that contain active peptides might affect daily self-antihypertensive management via enhancement or suppression of ACE inhibitory activity. 1. Introduction Tea polyphenols contained in green tea leaves (Camellia sinensis L.) are known to have antiviral [1], antioxidative [2, 3], antimutagenic [4], anticarcinogenic [5], antiobesity [6], and antihypertensive activities [7–9]. Tea leaves contain tea polyphenols such as catechins, so regular consumption of green tea is thought to be beneficial to one’s health. With rising health consciousness among consumers, particular attention has recently focused on green tea’s action to counter obesity and hypertension, which are diagnostic criteria for metabolic syndrome [10]. Tea beverages that contain high levels of tea polyphenols and that are labeled “For individuals worried about body fat” are being sold in Japan as foods for specified health uses (FOSHUs). Long-term consumption of tea has been reported to result in antihypertensive activity in spontaneously hypertensive rats (SHRs) [7, 8] while another study reported antihypertensive activity with a single administration of tea [9]. The antihypertensive activity of tea polyphenols is thought to occur via the inhibition of angiotensin-converting enzyme (ACE) activity [11]. Moreover, other FOSHUs, many of which have active components consisting of peptides that inhibit ACE activity, are marketed to target “individuals with high blood pressure” [12–14]. Indeed, tea beverages and FOSHUs can be readily obtained, so there may be instances in which they are consumed together. However, for individuals with high blood pressure, little is known about the antihypertensive interaction between tea and FOSHUs, which are both thought to have the same mechanisms of
References
[1]
S. Shiota, M. Shimizu, T. Mizushima, et al., “Marked reduction in the minimum inhibitory concentration (MIC) of β- lactams in methicillin-resistant Staphylococcus aureus produced by epicatechin gallate, an ingredient of green tea (Camellia sinensis),” Biological and Pharmaceutical Bulletin, vol. 22, no. 12, pp. 1388–1390, 1999.
[2]
T. Okuda, Y. Kimura, T. Yoshida, T. Hatano, H. Okuda, and S. Arichi, “Studies on the activities of tannins and related compounds from medicinal plants and drugs. I. Inhibitory effects on lipid peroxidation in mitochondria and microsomes of liver,” Chemical and Pharmaceutical Bulletin, vol. 31, no. 5, pp. 1625–1631, 1983.
[3]
A. Rietveld and S. Wiseman, “Antioxidant effects of tea: evidence from human clinical trials,” The Journal of Nutrition, vol. 133, no. 10, pp. 3285S–3292S, 2003.
[4]
T. Kada, K. Kaneko, S. Matsuzaki, T. Matsuzaki, and Y. Hara, “Detection and chemical identification of natural bio-antimutagens : a case of the green tea factor,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 150, no. 1-2, pp. 127–132, 1985.
[5]
H. Fujiki, M. Suganuma, S. Okabe, et al., “Cancer inhibition by green tea,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 402, no. 1-2, pp. 307–310, 1998.
[6]
T. Murase, A. Nagasawa, J. Suzuki, T. Hase, and I. Tokimitsu, “Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver,” International Journal of Obesity, vol. 26, no. 11, pp. 1459–1464, 2002.
[7]
M. A. Potenza, F. L. Marasciulo, M. Tarquinio, et al., “EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR,” American Journal of Physiology, vol. 292, no. 5, pp. E1378–E1387, 2007.
[8]
H. Negishi, J.-W. Xu, K. Ikeda, M. Njelekela, Y. Nara, and Y. Yamori, “Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats,” Journal of Nutrition, vol. 134, no. 1, pp. 38–42, 2004.
[9]
Y. Sagesaka-Mitane, T. Sugiura, Y. Miwa, K. Yamaguchi, and K. Kyuki, “Effect of tea-leaf saponin on blood pressure of spontaneously hypertensive rats,” Yakugaku Zasshi, vol. 116, no. 5, pp. 388–395, 1996.
[10]
K. G. M. M. Alberti, P. Zimmet, and J. Shaw, “The metabolic syndrome—a new worldwide definition,” The Lancet, vol. 366, no. 9491, pp. 1059–1062, 2005.
[11]
L. T. Skeggs, J. R. Khan, and N. P. Shumway, “Preparation and function of the hypertensin-converting enzyme,” The Journal of Experimental Medicine, vol. 103, no. 3, pp. 295–299, 1956.
[12]
Y. Nakamura, N. Yamamoto, K. Sakai, and T. Takano, “Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme,” Journal of Dairy Science, vol. 78, no. 6, pp. 1253–1257, 1995.
[13]
T. Kawasaki, E. Seki, K. Osajima, et al., “Antihypertensive effect of Valyl-Tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects,” Journal of Human Hypertension, vol. 14, no. 8, pp. 519–523, 2000.
[14]
D. Nakano, K. Ogura, M. Miyakoshi, et al., “Antihypertensive effect of angiotensin I-converting enzyme inhibitory peptides from a sesame protein hydrolysate in spontaneously hypertensive rats,” Bioscience, Biotechnology and Biochemistry, vol. 70, no. 5, pp. 1118–1126, 2006.
[15]
Y. Nakamura, N. Yamamoto, K. Sakai, A. Okubo, S. Yamazaki, and T. Takano, “Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk,” Journal of Dairy Science, vol. 78, no. 4, pp. 777–783, 1995.
[16]
T. Suzuki, N. Ishikawa, and H. Meguro, “Angiotensin I-converting enzyme inhibiting activity in foods (studies on vasodepressive components in foods. part I),” Nippon Nogeikagaku Kaishi, vol. 57, no. 11, pp. 1143–1146, 1983.
[17]
Y. Watanabe, K. Aburatani, T. Mizumura, et al., “Novel ELISA for the detection of raw and processed egg using extraction buffer containing a surfactant and a reducing agent,” The Journal of Immunological Methods, vol. 300, no. 1-2, pp. 115–123, 2005.
[18]
R. Jenness, “Inter-species comparison of milk proteins,” in Developments in Dairy Chemistry, P. F. Fox, Ed., pp. 87–114, Applied Science Publisher, London, UK, 1982.
[19]
M. G. L. Hertog, P. M. Sweetnam, A. M. Fehily, P. C. Elwood, and D. Kromhout, “Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly study,” American Journal of Clinical Nutrition, vol. 65, no. 5, pp. 1489–1494, 1997.
[20]
A. Papadopoulou and R. A. Frazier, “Characterization of protein-polyphenol interactions,” Trends in Food Science and Technology, vol. 15, no. 3-4, pp. 186–190, 2004.
[21]
K. J. Siebert, N. V. Troukhanova, and P. Y. Lynn, “Nature of polyphenol-protein interactions,” Journal of Agricultural and Food Chemistry, vol. 44, no. 1, pp. 80–85, 1996.
